DAY ONE BIOPHARMACEUTICALS I (DAWN) Stock Price & Overview
NASDAQ:DAWN • US23954D1090
The current stock price of DAWN is 21.2 USD. Today DAWN is up by 65.88%. In the past month the price increased by 18.99%. In the past year, price increased by 47.4%.
DAWN Key Statistics
- Market Cap
- 2.19B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.04
- Dividend Yield
- N/A
DAWN Stock Performance
DAWN Stock Chart
DAWN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to DAWN. When comparing the yearly performance of all stocks, DAWN is one of the better performing stocks in the market, outperforming 92.73% of all stocks.
DAWN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to DAWN. No worries on liquidiy or solvency for DAWN as it has an excellent financial health rating, but there are worries on the profitability.
DAWN Earnings
On February 24, 2026 DAWN reported an EPS of -0.21 and a revenue of 53.72M. The company missed EPS expectations (-35.56% surprise) and beat revenue expectations (8.44% surprise).
DAWN Forecast & Estimates
15 analysts have analysed DAWN and the average price target is 23.59 USD. This implies a price increase of 11.26% is expected in the next year compared to the current price of 21.2.
For the next year, analysts expect an EPS growth of 23.71% and a revenue growth 55.25% for DAWN
DAWN Groups
Sector & Classification
DAWN Financial Highlights
Over the last trailing twelve months DAWN reported a non-GAAP Earnings per Share(EPS) of -1.04. The EPS increased by 41.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.13% | ||
| ROE | -24.33% | ||
| Debt/Equity | 0 |
DAWN Ownership
DAWN Latest News, Press Relases and Analysis
DAWN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.85 | 410.651B | ||
| AMGN | AMGEN INC | 16.4 | 197.945B | ||
| GILD | GILEAD SCIENCES INC | 16.14 | 180.072B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 116.919B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.36 | 80.868B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.87 | 42.343B | ||
| INSM | INSMED INC | N/A | 30.619B | ||
| NTRA | NATERA INC | N/A | 27.941B | ||
| BIIB | BIOGEN INC | 12.15 | 27.603B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.01 | 21.26B | ||
| MRNA | MODERNA INC | N/A | 21.03B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.746B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.715B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DAWN
Company Profile
Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in Brisbane California, California and currently employs 178 full-time employees. The company went IPO on 2021-05-27. The company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. OJEMDA is used for the treatment of patients over six months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Its pipeline product candidates include DAY301 and Emi-Le (emiltatug ledadotin). DAY301 is a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. Emi-Le (emiltatug ledadotin) is a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).
Company Info
DAY ONE BIOPHARMACEUTICALS I
1800 Sierra Point Parkway, Suite 200
Brisbane California CALIFORNIA US
CEO: Jeremy Bender
Employees: 178
Phone: 16504840899
DAY ONE BIOPHARMACEUTICALS I / DAWN FAQ
Can you describe the business of DAY ONE BIOPHARMACEUTICALS I?
Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in Brisbane California, California and currently employs 178 full-time employees. The company went IPO on 2021-05-27. The company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. OJEMDA is used for the treatment of patients over six months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Its pipeline product candidates include DAY301 and Emi-Le (emiltatug ledadotin). DAY301 is a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. Emi-Le (emiltatug ledadotin) is a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).
What is the current price of DAWN stock?
The current stock price of DAWN is 21.2 USD. The price increased by 65.88% in the last trading session.
Does DAWN stock pay dividends?
DAWN does not pay a dividend.
What is the ChartMill rating of DAY ONE BIOPHARMACEUTICALS I stock?
DAWN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the growth outlook for DAY ONE BIOPHARMACEUTICALS I?
The Revenue of DAY ONE BIOPHARMACEUTICALS I (DAWN) is expected to grow by 55.25% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for DAWN stock?
DAY ONE BIOPHARMACEUTICALS I (DAWN) currently has 178 employees.
What is the Short Interest ratio of DAY ONE BIOPHARMACEUTICALS I (DAWN) stock?
The outstanding short interest for DAY ONE BIOPHARMACEUTICALS I (DAWN) is 12.27% of its float.